NMTC Neuroone Medical Technologies (NMTC) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001500198
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about NMTC
Insiders, 180 days
+$35.2K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Neuroone Medical Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NEUROONE MEDICAL TECHNOLOGIES Corp insiders bought a net $35.2K of stock across 33 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 1, 2026.
- The trade is 16.7% of the 199,999 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Wambeke David J. bought about $67.0K of NMTC on Aug 27, 2026.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Mar 30, 2026.
- The trade is 48.3% of the 20,692 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Market Development Director Christianson Mark sold about $31.8K of NMTC on Jun 30, 2026, the largest insider sale at the company since 2023.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Mar 13, 2026.
- The trade is 7.7% of the 198,920 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Business Development Director Christianson Mark sold about $11.4K of NMTC on Mar 30, 2026.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 12, 2026.
- The trade is 0.0% of the 214,283 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Business Development Director Christianson Mark sold about $80 of NMTC on Mar 13, 2026.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Mar 11, 2026.
- The trade is 0.4% of the 214,383 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Business Development Director Christianson Mark sold about $654 of NMTC on Mar 12, 2026.33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$35.2K over 180 days
+$67.0K over 90 days
more than 70% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+163.5% year over year
more than 96% of Medical Devices
Margin
-39.6% net margin
below 65% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.3% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 60% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NMTC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NMTC: institutional holders (13F)
13F holdings, latest reported quarter
$8.5K
$18
Congress trades in NMTC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NMTC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Christianson Mark
Filed 2026-06-30
$33.4K
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Not applicable
1 active
What changed recently
Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epi
2026-10-17 · Not Yet Recruiting → Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $35.2K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
NMTC financials
Revenue growth
+163.5%
XBRL, annual
Net margin
-39.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NMTC
| FY Sep 2025 | $9.1M |
| FY Sep 2024 | $3.5M |
| FY Sep 2023 | $2.0M |
| FY Sep 2022 | $171.2K |
| FY Sep 2021 | $178.1K |
| Jun 2026 | $2.0M |
| Mar 2026 | $2.4M |
| Dec 2025 | $2.9M |
| Sep 2025 | $2.7M |
| Jun 2025 | $1.7M |
| Mar 2025 | $1.4M |
| Dec 2024 | $3.3M |
| Sep 2024 | $272.3K |
At each fiscal year end
Single quarter
Net margin, TTM
-74.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NMTC
| FY Sep 2025 | -39.6% |
| FY Sep 2024 | -356.7% |
| FY Sep 2023 | -607.4% |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | -101.7% |
| Mar 2026 | -99.6% |
| Dec 2025 | -49.7% |
| Sep 2025 | -59.1% |
| Jun 2025 | -88.5% |
| Mar 2025 | -163.8% |
| Dec 2024 | +54.5% |
| Sep 2024 | -1,231% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NMTC
| FY Sep 2025 | -$2.9M |
| FY Sep 2024 | -$11.1M |
| FY Sep 2023 | -$13.3M |
| FY Sep 2022 | -$7.8M |
| FY Sep 2021 | n/a |
| Jun 2026 | -$1.1M |
| Mar 2026 | -$1.4M |
| Dec 2025 | -$3.2M |
| Sep 2025 | -$1.5M |
| Jun 2025 | -$1.5M |
| Mar 2025 | -$59.3K |
| Dec 2024 | $183.6K |
| Sep 2024 | -$2.7M |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end); equity 2026-06-30
Debt to equity NMTC
| FY Sep 2025 | 0.03x |
| FY Sep 2024 | 0.22x |
| FY Sep 2023 | 0.03x |
| FY Sep 2022 | 0.12x |
| FY Sep 2021 | 0.18x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.16x |
| Dec 2024 | 0.06x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-39.80x
TTM operating cash flow over long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end)
Cash flow to debt NMTC
| FY Sep 2025 | -16.01x |
| FY Sep 2024 | -62.15x |
| FY Sep 2023 | -69.89x |
| FY Sep 2022 | -6.67x |
| FY Sep 2021 | -7.11x |
| Jun 2026 | -39.80x |
| Mar 2026 | -41.96x |
| Dec 2025 | -34.77x |
| Sep 2025 | -16.01x |
| Jun 2025 | -22.45x |
| Mar 2025 | -27.52x |
| Dec 2024 | -39.48x |
| Sep 2024 | -62.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-124.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NMTC
| FY Sep 2025 | -91.3% |
| FY Sep 2024 | -348.4% |
| FY Sep 2023 | -149.6% |
| FY Sep 2022 | -123.8% |
| FY Sep 2021 | -230.8% |
| Jun 2026 | -124.7% |
| Mar 2026 | -223.8% |
| Dec 2025 | -146.3% |
| Sep 2025 | -91.3% |
| Jun 2025 | -95.4% |
| Mar 2025 | -265.2% |
| Dec 2024 | -195.5% |
| Sep 2024 | -348.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-87.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NMTC
| FY Sep 2025 | -44.6% |
| FY Sep 2024 | -182.9% |
| FY Sep 2023 | -113.4% |
| FY Sep 2022 | -96.3% |
| FY Sep 2021 | -156.7% |
| Jun 2026 | -87.6% |
| Mar 2026 | -115.4% |
| Dec 2025 | -90.6% |
| Sep 2025 | -44.6% |
| Jun 2025 | -67.8% |
| Mar 2025 | -134.1% |
| Dec 2024 | -116.7% |
| Sep 2024 | -182.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NMTC
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-116.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NMTC
| FY Sep 2025 | -72.6% |
| FY Sep 2024 | -251.3% |
| FY Sep 2023 | -149.2% |
| FY Sep 2022 | -121.7% |
| FY Sep 2021 | -223.1% |
| Jun 2026 | -116.7% |
| Mar 2026 | -171.8% |
| Dec 2025 | -124.9% |
| Sep 2025 | -72.6% |
| Jun 2025 | -89.9% |
| Mar 2025 | -201.0% |
| Dec 2024 | -144.9% |
| Sep 2024 | -251.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NMTC
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.5M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end), minus cash 2026-06-30
Enterprise value NMTC
| FY Sep 2025 | $260.3M |
| FY Sep 2024 | $181.7M |
| FY Sep 2023 | $122.6M |
| FY Sep 2022 | $157.3M |
| FY Sep 2021 | $278.7M |
| Jun 2026 | $24.6M |
| Mar 2026 | $232.9M |
| Dec 2025 | $225.9M |
| Sep 2025 | $260.3M |
| Jun 2025 | $194.8M |
| Mar 2025 | $156.3M |
| Dec 2024 | $151.9M |
| Sep 2024 | $181.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-97.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield NMTC
| FY Sep 2025 | -1.1% |
| FY Sep 2024 | -6.1% |
| FY Sep 2023 | -10.4% |
| FY Sep 2022 | -4.7% |
| FY Sep 2021 | n/a |
| Jun 2026 | -27.1% |
| Mar 2026 | -3.2% |
| Dec 2025 | -2.7% |
| Sep 2025 | -1.1% |
| Jun 2025 | -2.0% |
| Mar 2025 | -3.1% |
| Dec 2024 | -4.6% |
| Sep 2024 | -6.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NMTC
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171.2K |
| Gross profit | $5.1M | $1.1M | $456.5K | -$70.8K |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M |
| EPS (diluted) | -0.09 | -0.46 | -0.65 | -0.63 |
| Operating cash flow | -$2.8M | -$11.0M | -$12.9M | -$7.5M |
| Cash | $6.6M | $1.5M | $5.3M | $8.2M |
| Long-term debt | n/a | n/a | $55.3K | $119.6K |
SEC XBRL, fiscal years, as known on 2026-10-28
NMTC Stock Sonar score 5/7 axes
Find similar shapesCompareNMTC ranks highest on growth (96th percentile) and risk and compliance (66th), and lowest on profitability (20th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NMTC filings, in plain words
Are Neuroone Medical Technologies insiders buying or selling NMTC?
In the 180 days to 2026-10-28, Neuroone Medical Technologies insiders were net buyers, a net $35.2K: $67.0K of purchases and $31.8K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Neuroone Medical Technologies insiders were net buyers of NMTC, a net $35.2K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
